Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from manufacturing, marketing, selling, or distributing a generic version of such drug during any exclusivity period granted to manufacturers of generic brands.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.